Llwytho...
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report
BACKGROUND: Although the BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid leukaemia, it is associated with the risk of dasatinib-induced pulmonary arterial hypertension (DASA-PAH), for which predisposing factors have yet to be elucidated. However, animal studies...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Eur Heart J Case Rep |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6439368/ https://ncbi.nlm.nih.gov/pubmed/31020267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcr/ytz025 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|